Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Allograft Clear all
Completed Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 22, 2026, 10:43 AM EDT
Active, not recruiting No phase listed Observational

LAMBDA 002 (Lung Registry) Study

NCT05170425
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Prospera
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
California City, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 22, 2026, 10:43 AM EDT
Withdrawn Phase 1 Interventional

Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

NCT05340426
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
UKidney
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Predictors and Intervention for Noncompliance

NCT00148174
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Intensive telephone followup
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
14 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 22, 2026, 10:43 AM EDT
Terminated Not applicable Interventional Results available

Stem Cell Transplant for Hematological Malignancy

NCT00176930
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 22, 2026, 10:43 AM EDT
Terminated Not applicable Interventional Results available

Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

NCT01294007
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
PureGen Osteoprogenitor Cell Allograft, Autograft bone
Biological · Procedure
Lead sponsor
Alphatec Spine, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 22, 2026, 10:43 AM EDT
Completed No phase listed Observational

HLA Sensitization Following Major Cortical Allograft Bone Procedures

NCT00160719
View directory record Official record
Conditions
Bone Cancer
Interventions
retrieve blood samples
Procedure
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Noninvasive Evaluation of Renal Allograft Fibrosis by MRI

NCT04899167
View directory record Official record
Conditions
Kidney Transplantation
Interventions
MRI 1.5T and 3.0T
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 22, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor

NCT04954664
View directory record Official record
Conditions
Dental Implant, Bone Loss
Interventions
Allograft particles hydrated with rhPDGF, Allograft particles hydrated in a conventional way with saline.
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 22, 2026, 10:43 AM EDT
Active, not recruiting No phase listed Observational

Retrospective Study of AlloMend Acellular Dermal Matrix (ADM) Allograft and Pre-Pectoral Breast Reconstruction

NCT06853964
View directory record Official record
Conditions
Pre-Pectoral Breast Reconstruction Following Mastectomy
Interventions
AlloMend® Acellular Dermal Matrix allograft
Other
Lead sponsor
AlloSource
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

NCT01315132
View directory record Official record
Conditions
Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Hodgkin's Disease
Interventions
Matched Sibling Allogeneic Transplantation
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 22, 2026, 10:43 AM EDT
Enrolling by invitation No phase listed Observational

Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

NCT06000319
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Natural Matrix Protein (NMP) Fibers, Lumbar interbody fusion, Cervical interbody fusion
Biological · Procedure
Lead sponsor
Induce Biologics USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jasper, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

NCT00504634
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Sep 22, 2026, 10:43 AM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.

NCT01066637
View directory record Official record
Conditions
Patients With Post Orthotopic Heart Transplantation Status
Interventions
[18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Allogeneic Transplantation For Severe Osteopetrosis

NCT00775931
View directory record Official record
Conditions
Severe Osteopetrosis
Interventions
umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation
Procedure · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Amnios™ RT Outcomes Study

NCT04088383
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Amnios™ RT, Saline
Other
Lead sponsor
Globus Medical Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 22, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis

NCT03722537
View directory record Official record
Conditions
Basal Joint Arthritis
Interventions
Osteochondral Allograft, Ligament Reconstruction Tendon Interposition
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

NCT03641677
View directory record Official record
Conditions
Lung Diseases
Interventions
Centralized Lung Evaluation System, Lung Transplant
Device · Procedure
Lead sponsor
Lung Bioengineering Inc.
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

NCT03699631
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 22, 2026, 10:43 AM EDT
Completed No phase listed Observational

Clinical Trials in Organ Transplantation Extension Study

NCT04126746
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 22, 2026, 10:43 AM EDT
Completed No phase listed Observational

Hemostatic Textile to Control Bleeding at Donor Graft Sites

NCT00855569
View directory record Official record
Conditions
Wounds
Interventions
Stasilon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 22, 2026, 10:43 AM EDT